{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7170,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide combines a retrospective traction report with a mission/vision statement.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/4",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "team_bio",
      "function": "other",
      "notes": "Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/5",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Uses a Venn diagram to illustrate the intersection of Kinase Resistance and Kinase Selectivity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/6",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-6",
      "loopMatches": [
        {
          "to": 9,
          "from": 6,
          "name": "Jobs To Be Done",
          "slug": "53-jobs-to-be-done",
          "bestFor": "Product innovation, market entry, competitive positioning",
          "matchId": "7d073297-3453-4a5f-a314-d600119c06ad",
          "evidence": "The need for precisely targeted therapies is discussed.",
          "position": 2,
          "objective": "What are the unmet needs in cancer treatment?",
          "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
          "confidence": 0.6,
          "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 6,
          "from": 6,
          "beatId": "af08a215-8bda-49a9-b4de-9eba972cf7ae",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The solution of precisely targeted therapies is introduced.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/7",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-7",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
          "evidence": "The limitations of current treatments are discussed.",
          "position": 0,
          "objective": "What are the consequences of not addressing kinase resistance?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 9,
          "from": 6,
          "name": "Jobs To Be Done",
          "slug": "53-jobs-to-be-done",
          "bestFor": "Product innovation, market entry, competitive positioning",
          "matchId": "7d073297-3453-4a5f-a314-d600119c06ad",
          "evidence": "The need for precisely targeted therapies is discussed.",
          "position": 2,
          "objective": "What are the unmet needs in cancer treatment?",
          "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
          "confidence": 0.6,
          "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 7,
          "from": 7,
          "beatId": "b7fbf414-8df7-4ba0-a8a4-eda6bab91c20",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "The problem of kinase resistance is clearly stated.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit of selectivity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/8",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-8",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
          "evidence": "The limitations of current treatments are discussed.",
          "position": 0,
          "objective": "What are the consequences of not addressing kinase resistance?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 9,
          "from": 6,
          "name": "Jobs To Be Done",
          "slug": "53-jobs-to-be-done",
          "bestFor": "Product innovation, market entry, competitive positioning",
          "matchId": "7d073297-3453-4a5f-a314-d600119c06ad",
          "evidence": "The need for precisely targeted therapies is discussed.",
          "position": 2,
          "objective": "What are the unmet needs in cancer treatment?",
          "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
          "confidence": 0.6,
          "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/9",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-9",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
          "evidence": "The limitations of current treatments are discussed.",
          "position": 0,
          "objective": "What are the consequences of not addressing kinase resistance?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 9,
          "from": 6,
          "name": "Jobs To Be Done",
          "slug": "53-jobs-to-be-done",
          "bestFor": "Product innovation, market entry, competitive positioning",
          "matchId": "7d073297-3453-4a5f-a314-d600119c06ad",
          "evidence": "The need for precisely targeted therapies is discussed.",
          "position": 2,
          "objective": "What are the unmet needs in cancer treatment?",
          "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
          "confidence": 0.6,
          "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/10",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-10",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
          "evidence": "The limitations of current treatments are discussed.",
          "position": 0,
          "objective": "What are the consequences of not addressing kinase resistance?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 10,
          "beatId": "4cedff80-36c0-4bbc-a462-ced06248d8ee",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": null,
          "evidence": "The market for ROS1-positive NSCLC is sized.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/11",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-11",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
          "evidence": "The limitations of current treatments are discussed.",
          "position": 0,
          "objective": "What are the consequences of not addressing kinase resistance?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 11,
          "from": 11,
          "beatId": "7a498776-5a16-472f-bc57-dc9a095453a4",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Competitive Analysis",
          "beatSlug": "sequoia-pitch-competition",
          "evidence": "NVL-520 is compared to existing treatments.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/12",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-12",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
          "evidence": "The limitations of current treatments are discussed.",
          "position": 0,
          "objective": "What are the consequences of not addressing kinase resistance?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses dot plots for IC50 data and a bar chart for tumor regression efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/13",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a bar chart to compare brain penetrance and a grouped bar chart to show selectivity indices across multiple drugs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/14",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "Includes a detailed table of Phase 2 cohorts and a list of study objectives.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/15",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/16",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Clinical trial baseline characteristics table.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/17",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Data as of 13 Sep 22. Table lists specific adverse events by grade.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/18",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart displays dose-dependent exposure levels exceeding multiple efficacy targets (ROS1 G2032R and Wild Type in CNS and periphery).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/19",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-19",
      "loopMatches": [
        {
          "to": 24,
          "from": 19,
          "name": "Day In Life",
          "slug": "14-day-in-life",
          "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
          "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
          "evidence": "Preliminary efficacy data are presented.",
          "position": 1,
          "objective": "How do patients benefit from Nuvalent's therapies?",
          "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
          "confidence": 0.6,
          "description": "Humanize abstract data by walking through a single user's struggle and resolution"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 19,
          "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Preliminary efficacy and safety data are presented.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Clinical trial data presentation for NVL-520.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/20",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-20",
      "loopMatches": [
        {
          "to": 24,
          "from": 19,
          "name": "Day In Life",
          "slug": "14-day-in-life",
          "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
          "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
          "evidence": "Preliminary efficacy data are presented.",
          "position": 1,
          "objective": "How do patients benefit from Nuvalent's therapies?",
          "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
          "confidence": 0.6,
          "description": "Humanize abstract data by walking through a single user's struggle and resolution"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 19,
          "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Preliminary efficacy and safety data are presented.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/21",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-21",
      "loopMatches": [
        {
          "to": 24,
          "from": 19,
          "name": "Day In Life",
          "slug": "14-day-in-life",
          "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
          "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
          "evidence": "Preliminary efficacy data are presented.",
          "position": 1,
          "objective": "How do patients benefit from Nuvalent's therapies?",
          "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
          "confidence": 0.6,
          "description": "Humanize abstract data by walking through a single user's struggle and resolution"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 19,
          "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Preliminary efficacy and safety data are presented.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a swimmer plot (a common clinical trial visualization).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/22",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-22",
      "loopMatches": [
        {
          "to": 24,
          "from": 19,
          "name": "Day In Life",
          "slug": "14-day-in-life",
          "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
          "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
          "evidence": "Preliminary efficacy data are presented.",
          "position": 1,
          "objective": "How do patients benefit from Nuvalent's therapies?",
          "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
          "confidence": 0.6,
          "description": "Humanize abstract data by walking through a single user's struggle and resolution"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 19,
          "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Preliminary efficacy and safety data are presented.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/23",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-23",
      "loopMatches": [
        {
          "to": 24,
          "from": 19,
          "name": "Day In Life",
          "slug": "14-day-in-life",
          "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
          "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
          "evidence": "Preliminary efficacy data are presented.",
          "position": 1,
          "objective": "How do patients benefit from Nuvalent's therapies?",
          "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
          "confidence": 0.6,
          "description": "Humanize abstract data by walking through a single user's struggle and resolution"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 19,
          "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Preliminary efficacy and safety data are presented.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes patient case study images and clinical trial metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/24",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-24",
      "loopMatches": [
        {
          "to": 24,
          "from": 19,
          "name": "Day In Life",
          "slug": "14-day-in-life",
          "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
          "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
          "evidence": "Preliminary efficacy data are presented.",
          "position": 1,
          "objective": "How do patients benefit from Nuvalent's therapies?",
          "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
          "confidence": 0.6,
          "description": "Humanize abstract data by walking through a single user's struggle and resolution"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 19,
          "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Preliminary efficacy and safety data are presented.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "testimonial",
      "function": "illustrate_case",
      "notes": "Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/25",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "Slide 26 of a clinical presentation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/26",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a list of icons to represent key features of the drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/27",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/28",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/29",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/30",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/31",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/32",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
      "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "product_demo",
      "function": "present_solution",
      "notes": "The slide outlines the key therapeutic advantages of the drug candidate NVL-330.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/33",
      "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
      "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}